All In Biotech

Drug Trial Radar · NCT01206660

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Jul 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Aug 2010

Primary completion

Dec 2010

Study completion Jan 2011

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • Desoximetasone Spray 0.25%Drug

    Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days

  • placeboDrug

    Placebo administered to affected area twice a day for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Success ITTTime frame: 28 days
  2. Treatment SuccessTime frame: Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigator Site

    Hazleton, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.